FUSION ANTIBODIES PLC
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
FAB | IL
Overview
Corporate Details
- ISIN(s):
- GB00BDQZGK16
- LEI:
- 213800KBAYRC9VOQ9V39
- Country:
- United Kingdom
- Address:
- 1 SPRINGBANK ROAD, BT17 0QL BELFAST
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive range of antibody engineering services for therapeutic and diagnostic development. Established in 2001, the company functions as an end-to-end R&D partner, guiding projects from initial antigen design through discovery, engineering, and supply, to pre-clinical cell line development. Its core services include antibody generation, production, characterization, and optimization. Fusion Antibodies emphasizes a collaborative approach, working as an extension of its clients' teams to deliver biologics optimized for long-term manufacturability and commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-03 08:20 |
Regulatory News Service
OptiMAL® R&D Update
|
English | 16.5 KB | ||
| 2025-10-27 16:38 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.0 KB | ||
| 2025-10-16 14:31 |
Post-Annual General Meeting Information
Result of AGM
|
English | 15.7 KB | ||
| 2025-10-16 08:00 |
Post-Annual General Meeting Information
AGM statement and H1 trading update
|
English | 17.4 KB | ||
| 2025-09-19 13:58 |
Report Publication Announcement
Posting of Annual Report & Notice of AGM
|
English | 14.2 KB | ||
| 2025-09-17 08:00 |
Regulatory News Service
OptiMAL R&D Update
|
English | 21.3 KB | ||
| 2025-09-08 08:00 |
Report Publication Announcement
Belfast investor presentation
|
English | 15.2 KB | ||
| 2025-09-04 08:00 |
Earnings Release
Final Results
|
English | 439.7 KB | ||
| 2025-07-24 11:56 |
Legal Proceedings Report
Issue Notification: US Patent Update
|
English | 14.4 KB | ||
| 2025-07-11 08:00 |
Director's Dealing
Director/PDMR Shareholding
|
English | 24.7 KB | ||
| 2025-06-02 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 14.0 KB | ||
| 2025-05-06 11:53 |
Director's Dealing
Director/PDMR Shareholding
|
English | 24.0 KB | ||
| 2025-03-24 17:38 |
Major Shareholding Notification
Holding(s) in Company
|
English | 24.0 KB | ||
| 2025-03-18 08:00 |
Share Issue/Capital Change
Placing to raise approximately £1.17 million
|
English | 45.8 KB | ||
| 2025-02-27 08:00 |
Regulatory News Service
Contract win
|
English | 16.1 KB |
Automate Your Workflow. Get a real-time feed of all FUSION ANTIBODIES PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FUSION ANTIBODIES PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FUSION ANTIBODIES PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
